Abstract |
Interleukin (IL)-27 is a promising anti- cancer cytokine with therapeutic potential. Exhibiting overlapping properties with type I and II interferons (IFNs), IL-27 impacts cancer cell viability and immune cell activity. Known to modulate toll-like receptor (TLR) expression, we investigated whether IL-27 affected TLR-mediated death in cancer cells. Using DU145 and PC3 cell lines as models of prostate cancer, we investigated whether IL-27 and IFN-γ affect TLR3-mediated cell death. Our results demonstrate that when IL-27 or IFN-γ is added with polyinosinic-polycytidylic acid [ poly(I:C)], type I IFN (IFN-I) expression increases concurrently with cell death. IL-27 and IFN-γ enhanced TLR3 expression, suggesting a mechanism for sensitization to cell death. Further, PC3 cells were more sensitive to IL-27/ poly(I:C)-induced cell death compared with DU145 cells. This correlated with higher production of IFN-β and inducible protein-10 versus IL-6 in response to treatment of PC3 cells compared with DU145. Taken together, this study demonstrates a potential role for IL-27 in the treatment of prostate cancer.
|
Authors | Olena Kourko, Robin Smyth, Daniela Cino, Kyle Seaver, Carlene Petes, So Young Eo, Sam Basta, Katrina Gee |
Journal | Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research
(J Interferon Cytokine Res)
Vol. 39
Issue 8
Pg. 483-494
(08 2019)
ISSN: 1557-7465 [Electronic] United States |
PMID | 31009295
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Interleukin-27
- Poly I-C
|
Topics |
- Antineoplastic Agents
(pharmacology)
- Cell Death
(drug effects)
- Cell Proliferation
(drug effects)
- Dose-Response Relationship, Drug
- Drug Screening Assays, Antitumor
- Humans
- Interleukin-27
(pharmacology)
- Male
- PC-3 Cells
- Poly I-C
(pharmacology)
- Prostatic Neoplasms
(drug therapy, metabolism, pathology)
- Structure-Activity Relationship
- Tumor Cells, Cultured
|